Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,689,021

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Sanofi (SNY) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sanofi (SNY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Sanofi (SNY) closed at $45.18, marking a +1.3% move from the previous day.

Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA

by Zacks Equity Research

Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Esperion's Cholesterol Drugs Receive Approval in Europe

by Zacks Equity Research

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

Coronavirus Progress Boosts Investors' Sentiments

by Zacks Equity Research

Coronavirus Progress Boosts Investors' Sentiments.

Gilead Partners Second Genome, Boosts Coronavirus Drug Production

by Zacks Equity Research

Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.

Mark Vickery headshot

Markets Bullish on Coronavirus Progress

by Mark Vickery

"Flattening the curve" measures are beginning to bear fruit, as are announcements from myriad pharmaceutical companies vying to develop near-term therapeutics and longer-term vaccines for the coronavirus.

Kinjel Shah headshot

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

by Kinjel Shah

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis

by Zacks Equity Research

Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.

The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints

by Zacks Equity Research

Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates

by Kinjel Shah

J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.

Nilanjan Banerjee headshot

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

by Nilanjan Banerjee

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Sanofi to Withdraw Zantac After FDA Warns of Carcinogens

by Zacks Equity Research

The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.

Ekta Bagri headshot

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

by Ekta Bagri

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Gilead Expands Access to Experimental Coronavirus Treatment

by Zacks Equity Research

Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.

J&J Plans to Initiate Coronavirus Vaccine Study in September

by Zacks Equity Research

J&J (JNJ) announces its plan to start an early-stage clinical study on its selected vaccine candidate in September. The company also expands agreement with BARDA to accelerate vaccine development.

Sanofi (SNY) Catches Eye: Stock Jumps 5.3%

by Zacks Equity Research

Sanofi (SNY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Sanofi Begins Kevzara Study for Severe Coronavirus Infection

by Zacks Equity Research

Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir

by Zacks Equity Research

Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.